Xcout IntelSerenatis Bio
Serenatis Bio is a biotechnology company founded in 2024 and headquartered in Cambridge, United Kingdom. It is developing novel, precision therapeutics for obsessive-compulsive disorder (OCD).
Subscribe to see Serenatis Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Serenatis Bio at a glance
Serenatis Bio is a biotechnology company headquartered in United Kingdom. Its most recent funding round, Pre-Seed, closed in June 2025. Xcout tracks 5 named people at Serenatis Bio, including Julia Jones (CFO).
Serenatis Bio leadership
- Julia JonesCFO
- David CavallaCEO & Co-founder
- Nick SireauExecutive Chairman & Co-founder
- Natalie PankovaBoard Director
- Susanne StuffersBoard Director
Serenatis Bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Pre-Seed | Undisclosed | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Serenatis Bio competitors
A few of Serenatis Bio's closest competitors — see the full list of competitors and alternatives →
Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.
Lykos Therapeutics is a biotechnology company developing psychedelic-assisted therapies, particularly MDMA-assisted therapy for post-traumatic stress disorder (PTSD). It works with clinicians and researchers to advance regulated treatments for people with PTSD and related mental-health conditions.
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Reunion Neuroscience is a clinical-stage biopharmaceutical company that develops innovative therapeutics for underserved mental health disorders. Its lead drug candidate, luvesilocin, is a proprietary 5-HT2A agonist designed to provide durable antidepressant effects for patients with mood and anxiety disorders.
Get Serenatis Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Serenatis Bio in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access